For pharmaceutical companies, disruptors can accelerate the pace of drug development. Moderna Therapeutics has two big pharmaceutical partnerships to bring its products to market. It’s working with Merck to develop RNA-based vaccines and immunity therapies and with AstraZeneca on a range of therapeutic treatments for a number of cancers. The idea is to leverage both Moderna and its partners’ areas of expertise: Moderna leads the preclinical development, AstraZeneca then takes over early clinical development, and the two companies share the profits of product sales.
Finally, there’s Quid, which was a newcomer on the 2017 Disruptor 50 list. Asset manager Salient Partners uses Quid’s A.I. platform to drive the decision-making of its traders. Quid specializes in text-based data analysis, analyzing millions of documents, such as Amazon product reviews or News headlines. Salient uses Quid to understand how much the markets will be rattled by, say, the vote for Brexit.
Which start-ups will create the next wave of innovations that attract the attention of the public market’s prominent players? The call for nominations for CNBC’s 2018 Disruptor 50 list is under way: Find details and the nomination form at Disruptor50.cnbc.com.
Source : CNBC